Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study

Herbst R. S., de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H., ...More

Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, Switzerland, 11 - 14 December 2019, vol.30, pp.62-63, (Summary Text)

  • Publication Type: Conference Paper / Summary Text
  • Volume: 30
  • City: Geneva
  • Country: Switzerland
  • Page Numbers: pp.62-63
  • Istanbul University-Cerrahpasa Affiliated: No